<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232843</url>
  </required_header>
  <id_info>
    <org_study_id>EE04-01UK</org_study_id>
    <nct_id>NCT00232843</nct_id>
  </id_info>
  <brief_title>The Study to Treat Superficial Femoral Artery Occlusions.</brief_title>
  <acronym>SUPER UK</acronym>
  <official_title>A Clinical Investigation of the SMART™ Nitinol Self-Expandable Stent Versus Balloon Angioplasty Only for the Treatment of SUPERficial Femoral Artery Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the performance of the Cordis SMART™ nitinol&#xD;
      self-expandable stent for the treatment of superficial femoral artery (SFA) occlusions in&#xD;
      comparison with balloon angioplasty only as determined by binary restenosis at one year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, prospective, randomized, two-arm study evaluating the performance of&#xD;
      the Cordis SMART™ nitinol self-expanding stent as compared to angioplasty only.&#xD;
&#xD;
      It is anticipated that a total of 150 patients will be entered into the study. Patients will&#xD;
      be randomized on a 1:1 basis of stent versus angioplasty only.&#xD;
&#xD;
      150 patients with de novo or restenotic native SFA occlusions (5-22 cm) with reference vessel&#xD;
      of &gt;= 4.0 to &lt;= 6.0 mm in diameter will be randomized to the SMART™ nitinol self-expanding&#xD;
      stent or to angioplasty only.&#xD;
&#xD;
      All patients will be followed for 12 months post-procedure, by telephone contact at 3 and 6&#xD;
      months, and a 12 month clinical and duplex ultrasound assessment. This study will be&#xD;
      conducted at up to 12 investigational sites.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Binary restenosis as demonstrated by Duplex Ultrasound.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success.</measure>
    <time_frame>at time of deployment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success: defined as successful recanalization, without the occurrence of a SAE event.</measure>
    <time_frame>up to the moment the catheter sheath introducer has been removed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index</measure>
    <time_frame>at discharge and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis measured by Duplex Ultrasound</measure>
    <time_frame>at discharge and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cordis SMART™ nitinol self-expanding stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>balloon angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent</intervention_name>
    <description>Cordis SMART™ nitinol self-expanding stent.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cordis SMART™ nitinol self-expanding stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>angioplasty</intervention_name>
    <description>balloon angioplasty</description>
    <arm_group_label>2</arm_group_label>
    <other_name>balloon angioplasty</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  One superficial femoral artery de novo or restenotic lesion (&gt; 70% stenosis or&#xD;
             occlusions), with a lesion length &gt; 5 to &lt; 22 cm.&#xD;
&#xD;
          -  Patent popliteal artery on the index side, i.e., single vessel runoff or better with&#xD;
             at least one of three vessels patent to the lower 1/3 of the calf prior to the day of&#xD;
             the procedure. Additional intervention to further improve blood flow to the lower limb&#xD;
             is acceptable during the index procedure, but after successful treatment of the study&#xD;
             lesions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Revascularisation involving the same limb within 7 days prior to the index procedure&#xD;
             or a planned revascularisation within 7 days after the index procedure Patient having&#xD;
             total occlusions of the iliac artery on the same side must be excluded. However,&#xD;
             intervention to restore adequate blood flow is allowed during the same procedure and&#xD;
             prior to the treatment of the study lesion.&#xD;
&#xD;
          -  Patients enrolled in this or other clinical trial or anticipated to be included into a&#xD;
             trial, without written approval of the Cordis medical monitor and the principal&#xD;
             investigator of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Chalmers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Cowling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Staffordshire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire</name>
      <address>
        <city>Newcastle under Lyme</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <keyword>Peripheral Artery Occlusive Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

